This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Quotient Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Quotient şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-645.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-645.0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: U4W0 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: U4W0 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Quotient Piyasaya Karşı Temettü Getirisi

U4W0 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (U4W0)	n/a
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Medical Equipment)	2.0%
Analist tahmini (U4W0) (3 yıla kadar)	n/a

Önemli Temettü: U4W0 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, U4W0 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: U4W0 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: U4W0 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

This company listing is no longer active

Quotient Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought €140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings released: US$0.37 loss per share (vs US$0.27 loss in 1Q 2022)

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$1.23 loss per share (vs US$1.18 loss in FY 2021)

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought €70k worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought €91k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

New 90-day low: €3.90

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

Chief Commercial Officer recently sold €129k worth of stock

New 90-day low: €4.06

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

New 90-day high: €5.30

Second quarter 2021 earnings released: US$0.18 loss per share

Revenue beats expectations

Quotient Limited to Report Q2, 2021 Results on Nov 02, 2020

Quotient Limited Receives Receipt of U.S. FDA Emergency Use Authorization or Mosaiq COVID19 Antibody Test

Quotient Limited has completed a Follow-on Equity Offering in the amount of $75.000001 million.

New 90-day low - €4.54

New 90-day low - €5.60

Earnings released

Quotient Limited to Report Q1, 2021 Results on Aug 03, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin